MedTrace Logo

Contrast-enhanced Computed Tomography and Acute Kidney Injury

NCT07091656 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1463

Last updated 2025-07-29

No results posted yet for this study

Summary

Rationale and objectives: Since 1930 it has been accepted that intravenous injection of io-dinated contrast agent as part of contrast-enhanced computed tomography (CE-CT) imaging can induce a contrast-associated acute kidney injury (CA-AKI). For the last 10 years, studies have investigated this iatrogenia. However, those works didn't concern French population and particularly patient hospitalised after emergency department (ED) visit.

This study as-sessed the CA-AKI incidence and factor risks in patients hospitalised after a CE-CT in ED.

This was a retrospective cohort observational study in the ED of the Beaujon University Hospital between October 31st 2019 to January 24th 2022.

Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible. To be included, patients were required to have at least two creatinine measurements: one taken within 24 hours before CT and a second measurement taken between 48 hours to the seventh day following the initial test. The CT examination had to be performed at Beaujon Hospital with the injection of iodinated contrast agents such as IOMERON® (iomeprol) or XENETIX® (iobitridol).

Conditions

  • Contrast-associated Acute Kidney Injury

Interventions

OTHER

there is no intervention

NO INTERVENTION

Sponsors & Collaborators

  • Beaujon Hospital

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2022-01-24
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07091656 on ClinicalTrials.gov